Beckman Coulter, Protagen, Schunde Kangdi, Beijing PRC, Sage-N, Thermo Fisher, Pall Center of Excellence, Ariadne, Eurofins, Proteros, Boehringer Ingelheim | GenomeWeb
Beckman Coulter Backs Down, Biosite Says ‘Yes’ to Inverness
 
After a bidding war lasting more than a month, Biosite is on the verge of merging with Inverness Medical Innovations.
 
This week, Biosite said that it intends to accept a takeover bid by Inverness after its board determined the latest Inverness offer of $92.50 per share is superior to an offer by Beckman Coulter of $90 per share.
 
Beckman responded by saying it would not raise its bid.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.